Publications by authors named "Wu Zhuang"

Article Synopsis
  • - The study evaluated the effectiveness of HLX07, an anti-EGFR antibody, when used alone or in combination with serplulimab and chemotherapy for treating advanced esophageal squamous cell carcinoma (ESCC).
  • - In a trial with 50 patients, HLX07 alone showed a lower objective response rate (15.0%) and a shorter median progression-free survival (1.5 months), while the combination treatment had a higher response rate (60.0%) and longer median progression-free survival (7.8 months).
  • - Adverse effects were observed, with 10% of patients on HLX07 experiencing severe side effects, and 46.7% of those receiving the combination treatment facing similar grade 3-
View Article and Find Full Text PDF

Objectives: To observe the effect of simulated repeated transcranial acupuncture (rTAS) on learning and memory abilities and cerebral microvascular flow in vascular dementia (VD) model rats, so as to explore the potential mechanism of rTAS in treating VD.

Methods: Thirty-two Wistar rats were randomly divided into normal, model, acupuncture and rTAS groups (=8 rats in each group). The VD model was established by permanent ligation of bilateral common carotid arteries.

View Article and Find Full Text PDF
Article Synopsis
  • Zorifertinib is an experimental cancer drug that targets mutations in the EGFR gene and has shown effectiveness in patients with lung cancer that has spread to the brain.
  • A phase 3 trial compared zorifertinib to standard treatments and found that it significantly extended the time patients lived without the disease worsening (progression-free survival).
  • Results indicate that zorifertinib may be a better first-line treatment option for non-small cell lung cancer due to its ability to improve survival and manage side effects effectively.
View Article and Find Full Text PDF

Plasma epidermal growth factor receptor mutation (EGFRm) circulating tumor DNA (ctDNA) dynamics exhibit promise in predicting outcomes in patients with EGFRm-advanced non-small cell lung cancer (NSCLC). However, there remains limited trial-level data on integrating ctDNA monitoring into clinical practice. We performed a prospective, multicenter trial to investigate the relationship between EGFRm ctDNA dynamic changes and clinical outcomes in NSCLC patients with EGFRm.

View Article and Find Full Text PDF
Article Synopsis
  • SCT510 is a biosimilar to bevacizumab (Avastin) and was tested for its effectiveness, safety, and other factors in patients with advanced non-squamous non-small cell lung cancer (NSCLC).
  • The study included 567 eligible patients who were randomly assigned to receive either SCT510 or bevacizumab, showing similar objective response rates and no significant differences in other secondary endpoints regarding efficacy or safety.
  • Results indicate that SCT510 is equivalent to the reference product bevacizumab, which suggests it can be a viable alternative treatment option for patients with advanced NSCLC.
View Article and Find Full Text PDF

Introduction: KRAS glycine-to-cysteine substitution at codon 12 (G12C) mutation is a well-recognized and increasingly promising therapeutic target with huge unmet clinical needs in NSCLC patients. IBI351 is a potent covalent and irreversible inhibitor of KRAS G12C. Here, we present the efficacy and safety of IBI351 from an open-label, single-arm, phase 2 pivotal study.

View Article and Find Full Text PDF

Background: Xanthenes and multi-aryl carbon core containing compounds represent different types of complex and condensed architectures that have impressive wide range of pharmacological, industrial and synthetic applications. Moreover, indoles as building blocks were only found in naturally occurring metabolites with di-aryl carbon cores and in chemically synthesized tri-aryl carbon core containing compounds. Up to date, rare xanthenes with indole bearing multicaryl carbon core have been reported in natural or synthetic products.

View Article and Find Full Text PDF
Article Synopsis
  • The study analyzed the effectiveness of befotertinib, a drug for treating non-small cell lung cancer with EGFR T790M mutation, showing positive outcomes in patients with brain metastases and a manageable safety profile.
  • Two groups of patients received different doses of the drug, and after tracking their progress for nearly four years, the overall survival rates were reported as 23.9 months and 31.5 months for the lower and higher doses, respectively.
  • The results suggest that befotertinib offers significant overall survival benefits compared to other third-generation treatments, with adverse effects mostly manageable and in line with previous findings for similar cancer types.
View Article and Find Full Text PDF
Article Synopsis
  • Immunochemotherapy is the main treatment for extensive-stage small-cell lung cancer (ES-SCLC), and adding anti-angiogenesis may enhance its effectiveness.
  • The ETER701 trial tested a new treatment combining benmelstobart (a PD-L1 inhibitor) and anlotinib (an anti-angiogenic drug) with standard chemotherapy in newly diagnosed ES-SCLC patients.
  • The results showed that those receiving benmelstobart and anlotinib had significantly longer overall survival compared to the standard chemotherapy alone, with manageable side effects, indicating this combination could be a promising first-line treatment.
View Article and Find Full Text PDF
Article Synopsis
  • - The study focused on identifying risk factors and prognostic indicators for the spread of blepharospasm (BSP), a type of focal dystonia, through clinical and electrophysiological assessments over a 4-year period.
  • - Out of 136 patients observed, 45.6% experienced the spread of symptoms, with independent risk factors identified as high anxiety scores and specific EEG responses indicating nerve activity.
  • - A predictive model was developed to assess the risk of dystonic spread, showing strong accuracy in forecasting outcomes at multiple time intervals.
View Article and Find Full Text PDF

Background: Garsorasib (D-1553; InventisBio, Shangai, China), a potent KRAS inhibitor, has shown promising antitumour activity in patients with KRAS-mutated (ie, Gly12Cys) non-small-cell lung cancer (NSCLC) in a phase 1 study. We report results from a phase 2 study conducted to evaluate the efficacy and safety of garsorasib in patients with locally advanced or metastatic KRAS-mutated NSCLC.

Methods: This open-label, multicentre, single-arm, phase 2 trial enrolled adult patients with KRAS-mutated NSCLC who had previously been treated with platinum-based chemotherapy and immune checkpoint inhibitors from 43 hospitals in China.

View Article and Find Full Text PDF
Article Synopsis
  • Taletrectinib is a potent drug for treating non-small cell lung cancer that has shown high response rates and safety, particularly effective against the G2032R mutation.
  • In the TRUST-I study, 91% of treatment-naïve patients and 52% of those who had been treated with crizotinib experienced confirmed responses, with a median response duration not yet reached for naïve individuals.
  • The treatment's side effects were mostly mild, with low rates of severe neurologic issues, making it a promising option for patients with advanced lung cancer in China.
View Article and Find Full Text PDF

Objective: To explore the efficacy of serplulimab plus chemotherapy in esophageal squamous cell carcinoma (ESCC) patients with liver metastases.

Methods: A post hoc exploratory analysis of ASTRUM-007 study was performed, focusing on the association between the liver metastases status and the clinical outcomes. A systematic literature search of electronic databases was conducted to identify eligible randomized controlled trials for the meta-analysis.

View Article and Find Full Text PDF

Background: The emergence of the green supply chain represents a natural evolution from the traditional model. However, this transition has created trust concerns in operational processes. Fortunately, blockchain technology offers a promising solution to address this issue and help businesses overcome related obstacles.

View Article and Find Full Text PDF

Objective: Non-small cell lung cancer (NSCLC) is a prevailing LC characterized by poor outcomes. AlkB homolog 5 (ALKBH5) functions as a tumor suppressor in several cancers. This study delved into the role of ALKBH5 in NSCLC development.

View Article and Find Full Text PDF

With the growth of people's demand for loans, banks and other financial institutions put forward higher requirements for customer credit risk level classification, the purpose is to make better loan decisions and loan amount allocation and reduce the pre-loan risk. This article proposes a Multi-Level Classification based Ensemble and Feature Extractor (MLCEFE) that incorporates the strengths of sampling, feature extraction, and ensemble classification. MLCEFE uses SMOTE + Tomek links to solve the problem of data imbalance and then uses a deep neural network (DNN), auto-encoder (AE), and principal component analysis (PCA) to transform the original variables into higher-level abstract features for feature extraction.

View Article and Find Full Text PDF

Background: The initial phase II stuty (NCT03215693) demonstrated that ensartinib has shown clinical activity in patients with advanced crizotinib-refractory, anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Herein, we reported the updated data on overall survival (OS) and molecular profiling from the initial phase II study.

Methods: In this study, 180 patients received 225 mg of ensartinib orally once daily until disease progression, death or withdrawal.

View Article and Find Full Text PDF

With the increasing complexity of the electromagnetic environment, there is a growing demand for the manipulation of electromagnetic waves, leading to the rapid development in configurable microwave absorbers. All-dielectric absorbers offer broadband and high-intensity absorption effects in microwave absorption and shielding. However, they face a significant challenge: their performance is not adjustable once the design is completed.

View Article and Find Full Text PDF

Introduction: The acute levodopa challenge test (ALCT) is an important and valuable examination but there are still some shortcomings with it. We aimed to objectively assess ALCT based on a depth camera and filter out the best indicators.

Methods: Fifty-nine individuals with parkinsonism completed ALCT and the improvement rate (IR, which indicates the change in value before and after levodopa administration) of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS III) was calculated.

View Article and Find Full Text PDF

Purpose: To explore the impact of intrathecal pemetrexed (IP) on the survival of lung adenocarcinoma (LUAC) patients with leptomeningeal metastasis (LM).

Methods: We analyzed patients with LUAC and LM who received systemic therapy after LM diagnosis at the Fujian Cancer Hospital between July 2018 and March 2022. Patients who underwent IP were assigned to the IP group; those without IP treatment were designated as the non-IP group.

View Article and Find Full Text PDF

The mercaptomethyl radical (·CHSH) is a higher-energy isomer of the methylthio radical (CHS·) that has been proposed as an important intermediate in atmospheric and interstellar sulfur chemistry. Herein, we report the spectroscopic identification of ·CHSH during the UV (365 nm) photolysis of CHS· in a solid Ar-matrix at 10 K. Upon subsequent irradiation at 266 nm, the dehydrogenation of ·CHSH to yield CS via the intermediacy of the elusive thioformyl radical (HCS·) has also been observed.

View Article and Find Full Text PDF

Purpose: This study aimed to evaluate the efficacy and safety of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) in patients with previously treated metastatic non-small-cell lung cancer (NSCLC).

Methods: In this multicenter, open-label, phase Ib/II study, patients with previously treated NSCLC were enrolled in three different cohorts: Cohort A, patients who had failed previous platinum-based doublet chemotherapy and were immunotherapy naïve; Cohort B, patients who had failed previous platinum-based doublet chemotherapy and had primary resistance to immunotherapy (IO); Cohort C, patients who had failed previous platinum-based doublet chemotherapy and had acquired resistance to IO. Eligible patients were given cadonilimab 6 mg/kg intravenously every 2 weeks.

View Article and Find Full Text PDF

Background: Frailty is common in Parkinson's disease (PD) and increases vulnerability to adverse outcomes. Early detection of this syndrome aids in early intervention.

Aims: To objectively identify frailty at an early stage during routine motor tasks in PD patients using a Kinect-based system.

View Article and Find Full Text PDF